The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
FDA Lifts Clinical Hold on Phase II Trial of JCAR015 in ALL
July 13th 2016After less than a week, the FDA has lifted a clinical hold placed on the phase II ROCKET study that is exploring the CAR T-cell therapy JCAR015 for adult patients with relapsed or refractory B cell acute lymphoblastic leukemia.
Stadler Shares Treatment Updates, Questions in Castration-Sensitive Prostate Cancer
July 12th 2016Walter M. Stadler, MD, discusses emerging therapies, the most overriding challenges in a specific subset of patients, and understanding the evolving role of chemotherapy in metastatic castration-sensitive prostate cancer.
Survival Outcomes Affected by Tumor Location in KRAS Wild-Type mCRC
July 12th 2016The debate between the phase III CALGB/SWOG 80405 and FIRE-3 studies has been settled, as findings of a retrospective analysis of 80405 show that tumor location is significant in determining survival outcomes for patients with KRAS wild-type metastatic colorectal cancer.
Brose Discusses Lenvatinib's Lasting Impact in Treatment of Thyroid Cancer
July 11th 2016Marcia S. Brose, MD, PhD, discusses the updated SELECT findings, how practitioners are treating patients with lenvatinib, how its use compares with sorafenib, and the challenges that still exist with both therapies for patients with thyroid cancer.
TCH+P Still Standard Choice for Patients With HER2+ Breast Cancer
July 10th 2016Phase III results of the KRISTINE trial demonstrated that patients with HER2-positive early breast cancer had a significantly higher pathological complete response rate when they received the neoadjuvant regimen of docetaxel, carboplatin, and trastuzumab plus pertuzumab versus trastuzumab emtansine plus pertuzumab.
CDK4/6 Inhibitor Shows Promise as Single Agent in HR+ Breast Cancer
July 6th 2016Maura Dickler, MD, discusses findings from the recent phase II study exploring abemaciclib as a single agent in patients with HR-positive breast cancer, along with an upcoming phase III trial looking at combination strategies.
EC Grants Brentuximab Vedotin New Indication for Hodgkin Lymphoma
July 6th 2016The European Commission has approved brentuximab vedotin (Adcetris) for use as a consolidation therapy following autologous stem cell transplantation in patients with CD30-positive Hodgkin lymphoma at risk of relapse or progression.
CMS Announces Practices Participating in OCM and Launch Date
June 30th 2016A year after announcing its intention to launch the Oncology Care Model alternative payment plan for oncology care, The Centers for Medicare & Medicaid Services said it has 196 practices enrolled across the United States and that the official start date is Friday, July 1.
Pazdur Named Head of New Oncology Center of Excellence
June 30th 2016Richard Pazdur, MD, has been named the acting director of the FDA's newly created Oncology Center of Excellence, which is aimed to expedite the development of novel combination products and support an integrated approach to oncology research.